Acarix Receives Prestigious Digital Innovation Award in 2025
Acarix Celebrates Prestigious Digital Innovation Award
Highlighting groundbreaking advancements in digital and AI technologies shaping cardiovascular health.
Acarix, a leading innovator in AI and acoustic-based cardiac diagnostics, has been distinguished with the 2025 Digital Innovation Award at the Global Cardiovascular Awards, a recognition granted for their revolutionary CADScor® System.
Understanding the Digital Innovation Award
This esteemed award spotlights the impactful use of digital, mobile, and AI technologies in cardiovascular care. Acarix's CADScor System is at the forefront of this initiative, facilitating early diagnosis through a non-invasive, AI-driven method. It empowers healthcare professionals to effectively assess the risk of coronary artery disease (CAD) by aiding in the swift identification of patients experiencing stable chest pain who may require further examination.
Recognition for Excellence
Aamir Mahmood, President and CEO of Acarix, expresses his pride in receiving the Digital Innovation Award and mentions the honorable mention received for Innovation in Cardiac Imaging. He emphasizes, "This recognition signifies our dedication to enhancing patient outcomes through innovative AI and acoustic technology. With the CADScor System, clinicians can reach over 96% certainty in low-risk assessments, minimizing unnecessary procedures and streamlining patient management, which is transformative for both patients and healthcare professionals."
The Role of the Global Cardiovascular Awards
The Global Cardiovascular Awards are adjudicated by a prominent panel of international experts, including industry CEOs, clinical leaders, and influential figures in cardiovascular medicine. The selection of winners follows an extensive review of innovations that display a significant impact on cardiovascular health across the globe.
Celebrating Contributions
This awards ceremony aims to honor those who are actively shaping the future of cardiovascular care. It recognizes the efforts of researchers, clinicians, and organizations committed to advancing methods for preventing, diagnosing, and treating cardiovascular diseases.
About Acarix
Acarix, based in Sweden, is at the cutting edge of developing medical devices aimed at the early risk assessment of coronary artery disease (CAD) directly at the point of care. Their CADScor® System, which has CE-mark and FDA De Novo clearance, is specifically designed for patients exhibiting chest pain potentially indicative of CAD. By streamlining the diagnostic process, it helps decrease the necessity for invasive, costly diagnostic tests. Over 40,000 patients have benefited from the CADScor System, which utilizes highly sensitive acoustic detection coupled with advanced computational analysis to evaluate coronary blood flow and effectively rule out significant CAD with at least 96% certainty.
Company Listings and Advisory
Acarix is publicly traded on the Nasdaq First North Premier Growth Market in Stockholm under the ticker ACARIX and is also available on the OTCQB market in the U.S. with the ticker ACIXF. Carnegie Investment Bank acts as the company's Certified Advisor, supporting its strategic endeavors.
Contacting Acarix
For more insights and detailed information, individuals can visit www.acarix.com.
Media inquiries can be directed to Ashley Wilson at +1 405 413 5201.
Frequently Asked Questions
What is the CADScor System?
The CADScor System is a non-invasive, AI-driven diagnostic tool that helps assess the risk of coronary artery disease and improve patient care pathways.
Who is Acarix?
Acarix is a Swedish medical device company specializing in solutions for early risk assessment of coronary artery disease, integrating AI and acoustic technologies.
What recognition did Acarix receive at the Global Cardiovascular Awards?
Acarix received the 2025 Digital Innovation Award and an honorable mention for Innovation in Cardiac Imaging.
How does the CADScor System benefit patients?
The system reduces the need for invasive procedures and provides a rapid and accurate assessment of patients with suspected coronary artery disease.
What is the significance of the Global Cardiovascular Awards?
The awards recognize innovations that significantly impact cardiovascular health and are determined by a panel of esteemed experts in the field.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.